Posted On: 01/19/2016 8:29:45 AM
Post# of 72446
"Importantly, with respect to the planned Phase 2 trial for ovarian cancer, 8 of 11 subjects (73%) with advanced ovarian cancer had increases in p21 expression, indicative of activation of p53."
That quote was from today's release.
Only 3 did not have increases in p21. It seems dose dependent so the early, low doses were not enough BUT 73% for a terrible disease is a great start! We will refine the dosing in phase II
Finally, KEVETRIN is SAFE! The P-53 summit has been reached.
GO Dr. Mennon and Kevetrin!
That quote was from today's release.
Only 3 did not have increases in p21. It seems dose dependent so the early, low doses were not enough BUT 73% for a terrible disease is a great start! We will refine the dosing in phase II
Finally, KEVETRIN is SAFE! The P-53 summit has been reached.
GO Dr. Mennon and Kevetrin!
(0)
(0)
***On 02/26/2016 at 8:33 am Scottsmith admited to posting under 5 aliases but his post was subsequently deleted. I have a screen shot and will email it to anyone interested.
